BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38458259)

  • 1. European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy.
    Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Koerber SA; Debus J; Peeken JC; Vogel MME; Kroeze SGC; Guckenberger M; Krafcsik M; Hruby G; Emmett L; Schmidt-Hegemann NS; Trapp C; Spohn SKB; Henkenberens C; Mayer B; Shelan M; Aebersold DM; Thamm R; Wiegel T
    Radiother Oncol; 2024 May; 194():110215. PubMed ID: 38458259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
    Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T
    Radiother Oncol; 2023 Jul; 184():109678. PubMed ID: 37146766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
    Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Preisser F; Abrams-Pompe RS; Stelwagen PJ; Böhmer D; Zattoni F; Magli A; Rivas JG; Dilme RV; Sepulcri M; Eguibar A; Heidegger I; Arnold C; Fankhauser CD; Chun FK; van der Poel H; Gandaglia G; Wiegel T; van den Bergh RCN; Tilki D;
    Eur Urol; 2024 Feb; 85(2):164-170. PubMed ID: 37355358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
    Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
    Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy.
    Wenzel M; Hussein R; Maurer T; Karakiewicz PI; Tilki D; Graefen M; Würnschimmel C
    Urol Oncol; 2022 Jan; 40(1):7.e1-7.e8. PubMed ID: 34340868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
    World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
    Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
    J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
    BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
    Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement.
    Pak S; Lee DE; You D; Jeong IG; Joung JY; Lee KH; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2021 May; 39(5):298.e1-298.e6. PubMed ID: 33579626
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
    BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy.
    Falagario UG; Abbadi A; Remmers S; Björnebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
    JAMA Netw Open; 2023 Sep; 6(9):e2332900. PubMed ID: 37695584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Year Freedom from Progression After
    Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
    J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.